Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin for prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
2026-526857-33-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tinzaparin in venous thromboembolism (VTE) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Cumulative incidence of first venous thromboembolic event within 52 weeks. Planned start Sep 2026; status: authorised.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2026-526857-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526857-33-00.